#GNIGroup

Acquired shares of ZOO LABO Inc. on December 29, 2025, making it a consolidated subsidiary. Acquisition funds were raised through an overseas public offering in July 2025.

Consolidated subsidiary Gyre Therapeutics has completed prior consultation with China's CDE and confirmed that NDA submission utilizing the conditional approval system for F351 is possible and qualifies for priority review. NDA submission is targeted for the first half of 2026.